A phase 1b/pharmacokinetic trial of PTC299, a novel posttranscriptional VEGF inhibitor, for AIDS-related Kaposi's Sarcoma

AIDS malignancy consortium trial 059

for the AIDS Malignancy Consortium (AMC)-059 Study Team

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) plays an important role in Kaposi's sarcoma (KS). We administered PTC299, a post-transcriptional inhibitor of pathogenic VEGF, to persons with HIV-related KS. Seventeen participants received 3 different doses of PTC299. Adverse events typically observed with VEGF inhibition were absent. Three participants had partial tumor responses and 11 had stable disease. There were no differences in exposure to PTC299 by antiretroviral regimen. Serum VEGF, but not KS-associated herpesvirus DNA, decreased on treatment. Given redundancies in the VEGF feedback loop, future trials should consider combining PTC299 with agents that inhibit different pathways implicated in KS and KS-associated herpesvirus proliferation.

Original languageEnglish (US)
Pages (from-to)52-57
Number of pages6
JournalJournal of Acquired Immune Deficiency Syndromes
Volume72
Issue number1
DOIs
StatePublished - May 1 2016

Fingerprint

Vascular Endothelial Growth Factor A
Acquired Immunodeficiency Syndrome
Pharmacokinetics
Kaposi's Sarcoma
Human Herpesvirus 8
Neoplasms
AIDS-related Kaposi sarcoma
6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole
HIV
DNA
Serum

Keywords

  • HIV/AIDS-related malignancy
  • Kaposi's sarcoma (KS)
  • Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)
  • Pharmacokinetics (PK)
  • Vascular endothelial growth factor (VEGF)
  • Vascular endothelial growth factor inhibitor (VEGF inhibitor)

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

A phase 1b/pharmacokinetic trial of PTC299, a novel posttranscriptional VEGF inhibitor, for AIDS-related Kaposi's Sarcoma : AIDS malignancy consortium trial 059. / for the AIDS Malignancy Consortium (AMC)-059 Study Team.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 72, No. 1, 01.05.2016, p. 52-57.

Research output: Contribution to journalArticle

@article{f174d120e27043dc96c04d3f1ef1db00,
title = "A phase 1b/pharmacokinetic trial of PTC299, a novel posttranscriptional VEGF inhibitor, for AIDS-related Kaposi's Sarcoma: AIDS malignancy consortium trial 059",
abstract = "Vascular endothelial growth factor (VEGF) plays an important role in Kaposi's sarcoma (KS). We administered PTC299, a post-transcriptional inhibitor of pathogenic VEGF, to persons with HIV-related KS. Seventeen participants received 3 different doses of PTC299. Adverse events typically observed with VEGF inhibition were absent. Three participants had partial tumor responses and 11 had stable disease. There were no differences in exposure to PTC299 by antiretroviral regimen. Serum VEGF, but not KS-associated herpesvirus DNA, decreased on treatment. Given redundancies in the VEGF feedback loop, future trials should consider combining PTC299 with agents that inhibit different pathways implicated in KS and KS-associated herpesvirus proliferation.",
keywords = "HIV/AIDS-related malignancy, Kaposi's sarcoma (KS), Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8), Pharmacokinetics (PK), Vascular endothelial growth factor (VEGF), Vascular endothelial growth factor inhibitor (VEGF inhibitor)",
author = "{for the AIDS Malignancy Consortium (AMC)-059 Study Team} and Ignacio, {Rachel A Bender} and Lee, {Jeannette Y.} and Rudek, {Michelle A.} and Dittmer, {Dirk P.} and Ambinder, {Richard F.} and Krown, {Susan E.} and David Aboulafia and Robert Baiocchi and Chiao, {Elizabeth Y.} and Dezube, {Bruce J.} and Mitsuyasu, {Ronald T.} and Reid, {Erin Gourley} and Bruce Shiramizu and Sparano, {Joseph A.} and Anil Tulpule and Anthony Eason and Veenadhari Chavakula and Julia Lynne",
year = "2016",
month = "5",
day = "1",
doi = "10.1097/QAI.0000000000000918",
language = "English (US)",
volume = "72",
pages = "52--57",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - A phase 1b/pharmacokinetic trial of PTC299, a novel posttranscriptional VEGF inhibitor, for AIDS-related Kaposi's Sarcoma

T2 - AIDS malignancy consortium trial 059

AU - for the AIDS Malignancy Consortium (AMC)-059 Study Team

AU - Ignacio, Rachel A Bender

AU - Lee, Jeannette Y.

AU - Rudek, Michelle A.

AU - Dittmer, Dirk P.

AU - Ambinder, Richard F.

AU - Krown, Susan E.

AU - Aboulafia, David

AU - Baiocchi, Robert

AU - Chiao, Elizabeth Y.

AU - Dezube, Bruce J.

AU - Mitsuyasu, Ronald T.

AU - Reid, Erin Gourley

AU - Shiramizu, Bruce

AU - Sparano, Joseph A.

AU - Tulpule, Anil

AU - Eason, Anthony

AU - Chavakula, Veenadhari

AU - Lynne, Julia

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Vascular endothelial growth factor (VEGF) plays an important role in Kaposi's sarcoma (KS). We administered PTC299, a post-transcriptional inhibitor of pathogenic VEGF, to persons with HIV-related KS. Seventeen participants received 3 different doses of PTC299. Adverse events typically observed with VEGF inhibition were absent. Three participants had partial tumor responses and 11 had stable disease. There were no differences in exposure to PTC299 by antiretroviral regimen. Serum VEGF, but not KS-associated herpesvirus DNA, decreased on treatment. Given redundancies in the VEGF feedback loop, future trials should consider combining PTC299 with agents that inhibit different pathways implicated in KS and KS-associated herpesvirus proliferation.

AB - Vascular endothelial growth factor (VEGF) plays an important role in Kaposi's sarcoma (KS). We administered PTC299, a post-transcriptional inhibitor of pathogenic VEGF, to persons with HIV-related KS. Seventeen participants received 3 different doses of PTC299. Adverse events typically observed with VEGF inhibition were absent. Three participants had partial tumor responses and 11 had stable disease. There were no differences in exposure to PTC299 by antiretroviral regimen. Serum VEGF, but not KS-associated herpesvirus DNA, decreased on treatment. Given redundancies in the VEGF feedback loop, future trials should consider combining PTC299 with agents that inhibit different pathways implicated in KS and KS-associated herpesvirus proliferation.

KW - HIV/AIDS-related malignancy

KW - Kaposi's sarcoma (KS)

KW - Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)

KW - Pharmacokinetics (PK)

KW - Vascular endothelial growth factor (VEGF)

KW - Vascular endothelial growth factor inhibitor (VEGF inhibitor)

UR - http://www.scopus.com/inward/record.url?scp=84951304513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951304513&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000000918

DO - 10.1097/QAI.0000000000000918

M3 - Article

VL - 72

SP - 52

EP - 57

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 1

ER -